Transplantation of hematopoietic stem cells has been widely used as an approved treatment of leukemia, lymphoma and certain autoimmune conditions for the past fifty years. Other adult stem cells have demonstrated safety and efficacy in pre-clinical research and clinical trials. Mesenchymal stem cell transplants have been most widely studied in animals, especially horses & dogs, and humans. Many of these studies have focused on skeletal-muscular effects.
There is significant support for safety and efficacy in osteoarthritis, including cartilage regeneration, pain and inflammation reduction as well as recovery of function using intra-articular MSC injections. There are fewer studies of neural stem
Image via Wikipedia
Discovery sheds new light on the process of stem cell generation, and will help promote safer stem-cell based studies and future clinical trials.
Dr. Andras Nagy’s laboratory at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital and Dr. Timo Otonkoski’s laboratory at Biomedicum Stem Cell Center (University of Helsinki), as well as collaborators in Europe and Canada have identified genetic abnormalities associated with reprogramming adult cells to induced pluripotent stem (iPS) cells. The findings give researchers new insights into the reprogramming process, and will help make future applications of stem cell creation and subsequent use safer.
The brave new world of stem cell research dangles the exciting potential for a host of leading-edge treatments that may one day help cure debilitating diseases such as Alzheimer’s, Parkinson’s and other maladies that today cannot be treated with modern medicine.
However, not much thought has been given to how those products might be regulated and how issues of legal liability may be addressed in a way that encourages scientific innovation but also protects the patients for whom these treatments might provide great relief.
Now, an attorney and law professor from the UCLA School of Law and a member of the
Until recently, when a patient suffering a heart attack arrived at a hospital, doctors could open the blocked blood vessel and restore blood flow to prevent further damage. But there was nothing they could do to reverse the harm already done. That damage — scarring that can kill up to 50 percent of the heart — leaves patients with difficulty breathing, loss of energy and the inability to do things such as walk up stairs. Some patients need transplants. And some end up with hearts so weak they die.
The solution: Now doctors can repair that damage. In
A first-of-its-kind study is just getting underway at University of Minnesota Physicians Heart at Fairview, in Minneapolis. The FDA-approved trial is designed to test the impact of stem cells on restoring the heart’s muscle function in patients suffering from advanced heart failure. The results of the trial could impact the future of health care in the area of heart disease, and may one day save lives (…)
“This trial is designed for heart failure patients in the end stage of heart failure, with no options for treatment,” explained Ganesh Raveendran, M.D., who is the principal investigator of the clinical trial.